Endocrine disrupters as obesogens

Molecular and Cellular Endocrinology

Volumn 304, Issue 1-2, 2009, Pages 19-29

  Grün, Felix ^a   Blumberg, Bruce ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endocrine disrupter; Environmental agents; Nuclear receptor; Obesity; Obesogen; Organotin

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; DIETHYLSTILBESTROL; ENDOCANNABINOID; ENDOCRINE DISRUPTOR; JTP 426467; MIFOBATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BIOSENSOR; BUDGET; DRUG EXPOSURE; DRUG MEGADOSE; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; ENERGY BALANCE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXERCISE; HEALTH CARE PLANNING; HEALTH PROGRAM; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; NEUROENDOCRINE SYSTEM; NONHUMAN; NUTRIENT; OBESITY; OVERNUTRITION; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STRESS; WEIGHT CONTROL;

ANIMALS; CALORIC RESTRICTION; ENDOCRINE DISRUPTORS; ENDOCRINE SYSTEM; ENERGY METABOLISM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; GONADAL STEROID HORMONES; HUMANS; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RETINOID X RECEPTORS;

EID: 67349154088     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.02.018     Document Type: Review

References (206)

1. Abbott B.D., Wolf C.J., Schmid J.E., Das K.P., Zehr R.D., Helfant L., Nakayama S., Lindstrom A.B., Strynar M.J., and Lau C. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol. Sci. 98 (2007) 571-581
2. Abdellatif A.G., Preat V., Taper H.S., and Roberfroid M. The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. Toxicol. Appl. Pharmacol. 111 (1991) 530-537
3. Achard V., Boullu-Ciocca S., Desbriere R., and Grino M. Perinatal programming of central obesity and the metabolic syndrome: role of glucocorticoids. Metab. Syndr. Relat. Disord. 4 (2006) 129-137
4. Al Mamun A., Lawlor D.A., Alati R., O'Callaghan M.J., Williams G.M., and Najman J.M. Does maternal smoking during pregnancy have a direct effect on future offspring obesity? Evidence from a prospective birth cohort study. Am. J. Epidemiol. 164 (2006) 317-325
5. Alonso A., Marti A., Corbalan M.S., Martinez-Gonzalez M.A., Forga L., and Martinez J.A. Association of UCP3 gene -55C > T polymorphism and obesity in a Spanish population. Ann. Nutr. Metab. 49 (2005) 183-188
6. Andersson U., Filipsson K., Abbott C.R., Woods A., Smith K., Bloom S.R., Carling D., and Small C.J. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279 (2004) 12005-12008
7. Apelberg B.J., Witter F.R., Herbstman J.B., Calafat A.M., Halden R.U., Needham L.L., and Goldman L.R. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ. Health Perspect. 115 (2007) 1670-1676
8. Arias Horcajadas F. Cannabinoids in eating disorders and obesity. Mol. Neurobiol. 36 (2007) 113-128
9. Asakawa A., Toyoshima M., Fujimiya M., Harada K., Ataka K., Inoue K., and Koizumi A. Perfluorooctane sulfonate influences feeding behavior and gut motility via the hypothalamus. Int. J. Mol. Med. 19 (2007) 733-739
10. Asakawa A., Toyoshima M., Harada K.H., Fujimiya M., Inoue K., and Koizumi A. The ubiquitous environmental pollutant perfluorooctanoicacid inhibits feeding behavior via peroxisome proliferator-activated receptor-alpha. Int. J. Mol. Med. 21 (2008) 439-445
11. Atanasov A.G., Tam S., Rocken J.M., Baker M.E., and Odermatt A. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. Biochem. Biophys. Res. Commun. 308 (2003) 257-262
12. Atanasov A.G., Nashev L.G., Tam S., Baker M.E., and Odermatt A. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ. Health Perspect. 113 (2005) 1600-1606
13. Baptista T., De Mendoza S., Beaulieu S., Bermudez A., and Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab. Syndr. Relat. Disord. 2 (2004) 290-307
14. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., and Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349 (2003) 941-948
15. Bell F.P. Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals. Environ. Health Perspect. 45 (1982) 41-50
16. Betts K.S. Perfluoroalkyl acids: what is the evidence telling us?. Environ. Health Perspect. 115 (2007) A250-256
17. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 13 (1997) 795-803
18. Bjorntorp P., and Rosmond R. Obesity and cortisol. Nutrition 16 (2000) 924-936
19. Bluher M., Engeli S., Kloting N., Berndt J., Fasshauer M., Batkai S., Pacher P., Schon M.R., Jordan J., and Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
20. Boullu-Ciocca S., Dutour A., Guillaume V., Achard V., Oliver C., and Grino M. Postnatal diet-induced obesity in rats upregulates systemic and adipose tissue glucocorticoid metabolism during development and in adulthood: its relationship with the metabolic syndrome. Diabetes 54 (2005) 197-203
21. Boyer I.J. Toxicity of dibutyltin, tributyltin and other organotin compounds to humans and to experimental animals. Toxicology 55 (1989) 253-298
22. Braga-Basaria M., Dobs A.S., Muller D.C., Carducci M.A., John M., Egan J., and Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 24 (2006) 3979-3983
23. Campfield L.A., Smith F.J., Guisez Y., Devos R., and Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269 (1995) 546-549
24. Carfi M., Croera C., Ferrario D., Campi V., Bowe G., Pieters R., and Gribaldo L. TBTC induces adipocyte differentiation in human bone marrow long term culture. Toxicology (2008)
25. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am. J. Med. 118 Suppl 2 (2005) 15S-22S
26. Centers for Disease Control and Prevention, 2005. Third National Report on Human Exposure to Environmental Chemicals. CDC, Atlanta, GA.
27. Cha M.H., Shin H.D., Kim K.S., Lee B.H., and Yoon Y. The effects of uncoupling protein 3 haplotypes on obesity phenotypes and very low-energy diet-induced changes among overweight Korean female subjects. Metabolism 55 (2006) 578-586
28. Cheshenko K., Pakdel F., Segner H., Kah O., and Eggen R.I. Interference of endocrine disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish. Gen. Comp. Endocrinol. 155 (2008) 31-62
29. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63 (1998) PL113-PL117
30. Cooke G.M. Effect of organotins on human aromatase activity in vitro. Toxicol. Lett. 126 (2002) 121-130
31. Cooke P.S., and Naaz A. Effects of estrogens and the phytoestrogen genistein on adipogenesis and lipogenesis in males and females. Birth Defects Res. A Clin. Mol. Teratol. 73 (2005) 472-473
32. Cooke G.M., Forsyth D.S., Bondy G.S., Tachon R., Tague B., and Coady L. Organotin speciation and tissue distribution in rat dams, fetuses, and neonates following oral administration of tributyltin chloride. J. Toxicol. Environ. Health A 71 (2008) 384-395
33. Cooney C.A., Dave A.A., and Wolff G.L. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J. Nutr. 132 (2002) 2393S-2400S
34. Corp E.S., Curcio M., Gibbs J., and Smith G.P. The effect of centrally administered CCK-receptor antagonists on food intake in rats. Physiol. Behav. 61 (1997) 823-827
35. Cota D., Proulx K., and Seeley R.J. The role of CNS fuel sensing in energy and glucose regulation. Gastroenterology 132 (2007) 2158-2168
36. Cottrell E.C., and Ozanne S.E. Developmental programming of energy balance and the metabolic syndrome. Proc. Nutr. Soc. 66 (2007) 198-206
37. Covaci A., Voorspoels S., Roosens L., Jacobs W., Blust R., and Neels H. Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in human liver and adipose tissue samples from Belgium. Chemosphere (2008)
38. Croutch C.R., Lebofsky M., Schramm K.W., Terranova P.F., and Rozman K.K. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1, 2, 3, 4, 7, 8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. Toxicol. Sci. 85 (2005) 560-571
39. Csaba G., and Inczefi-Gonda A. Transgenerational effect of a single neonatal benzpyrene treatment on the glucocorticoid receptor of the rat thymus. Hum. Exp. Toxicol. 17 (1998) 88-92
40. Danilovich N., Babu P.S., Xing W., Gerdes M., Krishnamurthy H., and Sairam M.R. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 141 (2000) 4295-4308
41. de Jesus L.A., Carvalho S.D., Ribeiro M.O., Schneider M., Kim S.W., Harney J.W., Larsen P.R., and Bianco A.C. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J. Clin. Invest. 108 (2001) 1379-1385
42. Drake A.J., Walker B.R., and Seckl J.R. Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R34-R38
43. Dy J., Guan H., Sampath-Kumar R., Richardson B.S., and Yang K. Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery. Placenta 29 (2008) 193-200
44. Ellis-Hutchings R.G., Cherr G.N., Hanna L.A., and Keen C.L. Polybrominated diphenyl ether (PBDE)-induced alterations in vitamin A and thyroid hormone concentrations in the rat during lactation and early postnatal development. Toxicol. Appl. Pharmacol. 215 (2006) 135-145
45. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
46. Farooqi I.S., and O'Rahilly S. Monogenic human obesity syndromes. Recent Prog. Horm. Res. 59 (2004) 409-424
47. Feige J.N., Gelman L., Rossi D., Zoete V., Metivier R., Tudor C., Anghel S.I., Grosdidier A., Lathion C., Engelborghs Y., Michielin O., Wahli W., and Desvergne B. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J. Biol. Chem. 282 (2007) 19152-19166
48. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1 (2004) S43-50
49. Festuccia W.T., Oztezcan S., Laplante M., Berthiaume M., Michel C., Dohgu S., Denis R.G., Brito M.N., Brito N.A., Miller D.S., Banks W.A., Bartness T.J., Richard D., and Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149 (2008) 2121-2130
50. Fetissov S.O., Huang P., Zhang Q., Mimura J., Fujii-Kuriyama Y., Rannug A., Hokfelt T., and Ceccatelli S. Expression of hypothalamic neuropeptides after acute TCDD treatment and distribution of Ah receptor repressor. Regul. Pept. 119 (2004) 113-124
51. Fiorito M., Torrente I., De Cosmo S., Guida V., Colosimo A., Prudente S., Flex E., Menghini R., Miccoli R., Penno G., Pellegrini F., Tassi V., Federici M., Trischitta V., and Dallapiccola B. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obes. (Silver Spring) 15 (2007) 2889-2895
52. Fisher J.S. Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. Reproduction 127 (2004) 305-315
53. Fromme H., Mattulat A., Lahrz T., and Ruden H. Occurrence of organotin compounds in house dust in Berlin (Germany). Chemosphere 58 (2005) 1377-1383
54. Frontera M., Dickins B., Plagge A., and Kelsey G. Imprinted genes, postnatal adaptations and enduring effects on energy homeostasis. Adv. Exp. Med. Biol. 626 (2008) 41-61
55. Gao Q., and Horvath T.L. Cross-talk between estrogen and leptin signaling in the hypothalamus. Am. J. Physiol. Endocrinol. Metab. 294 (2008) E817-E826
56. Garbrecht M.R., Krozowski Z.S., Snyder J.M., and Schmidt T.J. Reduction of glucocorticoid receptor ligand binding by the 11-beta hydroxysteroid dehydrogenase type 2 inhibitor. Thiram. Steroids 71 (2006) 895-901
57. Gazzerro P., Caruso M.G., Notarnicola M., Misciagna G., Guerra V., Laezza C., and Bifulco M. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int. J. Obes. (Lond.) 31 (2007) 908-912
58. Goldberg R.B. The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?. Curr. Opin. Lipidol. 18 (2007) 435-442
59. Goodman-Gruen D., and Kritz-Silverstein D. Usual dietary isoflavone intake and body composition in postmenopausal women. Menopause 10 (2003) 427-432
60. Gray Jr. L.E., Ostby J., Furr J., Price M., Veeramachaneni D.N., and Parks L. Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicol. Sci. 58 (2000) 350-365
61. Greenberg I., Kuehnle J., Mendelson J.H., and Bernstein J.G. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl.) 49 (1976) 79-84
62. Grun F., and Blumberg B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev. Endocr. Metab. Disord. 8 (2007) 161-171
63. Grun F., Watanabe H., Zamanian Z., Maeda L., Arima K., Chubacha R., Gardiner D.M., Kanno J., Iguchi T., and Blumberg B. Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol. Endocrinol. 9 (2006) 2141-2155
64. Guerin T., Sirot V., Volatier J.L., and Leblanc J.C. Organotin levels in seafood and its implications for health risk in high-seafood consumers. Sci. Total Environ. 388 (2007) 66-77
65. Gumy C., Chandsawangbhuwana C., Dzyakanchuk A.A., Kratschmar D.V., Baker M.E., and Odermatt A. Dibutyltin disrupts glucocorticoid receptor function and impairs glucocorticoid-induced suppression of cytokine production. PLoS ONE 3 (2008) e3545
66. Hales C.N., and Barker D.J. The thrifty phenotype hypothesis. Br. Med. Bull. 60 (2001) 5-20
67. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., Hagura R., Akanuma Y., Kimura S., Ito C., and Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271 (2000) 212-216
68. Heidrich D.D., Steckelbroeck S., and Klingmuller D. Inhibition of human cytochrome P450 aromatase activity by butyltins. Steroids 66 (2001) 763-769
69. Heine P.A., Taylor J.A., Iwamoto G.A., Lubahn D.B., and Cooke P.S. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12729-12734
70. Henley D.V., and Korach K.S. Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. Endocrinology 147 (2006) S25-32
71. Herrmann S.M., Wang J.G., Staessen J.A., Kertmen E., Schmidt-Petersen K., Zidek W., Paul M., and Brand E. Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. J. Mol. Med. 81 (2003) 327-332
72. Hildebrandt A.L., Kelly-Sullivan D.M., and Black S.C. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 462 (2003) 125-132
73. Hoppe A.A., and Carey G.B. Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism. Obes. (Silver Spring) 15 (2007) 2942-2950
74. Horiguchi T. Masculinization of female gastropod mollusks induced by organotin compounds, focusing on mechanism of actions of tributyltin and triphenyltin for development of imposex. Environ. Sci. 13 (2006) 77-87
75. Hurst C.H., and Waxman D.J. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol. Sci. 74 (2003) 297-308
76. Ikeda T., Aiba K., Fukuda K., and Tanaka M. The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. J. Biochem. 98 (1985) 475-482
77. Inadera H., and Shimomura A. Environmental chemical tributyltin augments adipocyte differentiation. Toxicol. Lett. (2005)
78. Inoue K., Kato K., Yoshimura Y., Makino T., and Nakazawa H. Determination of bisphenol A in human serum by high-performance liquid chromatography with multi-electrode electrochemical detection. J. Chromatogr. B Biomed. Sci. Appl. 749 (2000) 17-23
79. Ishikura N., Tsunashima K., Watanabe K., Nishimura T., Minabe Y., and Kato N. Neuropeptide Y and somatostatin participate differently in the seizure-generating mechanisms following trimethyltin-induced hippocampal damage. Neurosci. Res. 44 (2002) 237-248
80. Itsuki-Yoneda A., Kimoto M., Tsuji H., Hiemori M., and Yamashita H. Effect of a hypolipidemic drug, Di (2-ethylhexyl) phthalate, on mRNA-expression associated fatty acid and acetate metabolism in rat tissues. Biosci. Biotechnol. Biochem. 71 (2007) 414-420
81. Janer G., Navarro J.C., and Porte C. Exposure to TBT increases accumulation of lipids and alters fatty acid homeostasis in the ramshorn snail Marisa cornuarietis. Comp. Biochem. Physiol. C Toxicol. Pharmacol. (2007)
82. Jarfelt K., Dalgaard M., Hass U., Borch J., Jacobsen H., and Ladefoged O. Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate. Reprod. Toxicol. 19 (2005) 505-515
83. Jensen A.A., and Leffers H. Emerging endocrine disrupters: perfluoroalkylated substances. Int. J. Androl. 31 (2008) 161-169
84. Jones M.E., Thorburn A.W., Britt K.L., Hewitt K.N., Wreford N.G., Proietto J., Oz O.K., Leury B.J., Robertson K.M., Yao S., and Simpson E.R. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12735-12740
85. Kanayama T., Kobayashi N., Mamiya S., Nakanishi T., and Nishikawa J. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. Mol. Pharmacol. 67 (2005) 766-774
86. Kannan K., Senthilkumar K., and Giesy J. Occurrence of butyltin compounds in human blood. Environ. Sci. Tech. 33 (1999) 1776-1779
87. Kaufman D., Banerji M.A., Shorman I., Smith E.L., Coplan J.D., Rosenblum L.A., and Kral J.G. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. Diabetes 56 (2007) 1382-1386
88. Kershaw E.E., Morton N.M., Dhillon H., Ramage L., Seckl J.R., and Flier J.S. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54 (2005) 1023-1031
89. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., and Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003) 3095-3105
90. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 617-627
91. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 18 (2008) 141-144
92. Kim M.S., Yoon C.Y., Jang P.G., Park Y.J., Shin C.S., Park H.S., Ryu J.W., Pak Y.K., Park J.Y., Lee K.U., Kim S.Y., Lee H.K., Kim Y.B., and Park K.S. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. Mol. Endocrinol. 18 (2004) 2291-2301
93. Kim H.K., Nelson-Dooley C., Della-Fera M.A., Yang J.Y., Zhang W., Duan J., Hartzell D.L., Hamrick M.W., and Baile C.A. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J. Nutr. 136 (2006) 409-414
94. Kim S.F., Huang A.S., Snowman A.M., Teuscher C., and Snyder S.H. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 3456-3459
95. Klebig M.L., Wilkinson J.E., Geisler J.G., and Woychik R.P. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4728-4732
96. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., Mitchell S.E., Williams L.M., Hawley S.A., Hardie D.G., Grossman A.B., and Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280 (2005) 25196-25201
97. Kola B., Farkas I., Christ-Crain M., Wittmann G., Lolli F., Amin F., Harvey-White J., Liposits Z., Kunos G., Grossman A.B., Fekete C., and Korbonits M. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3 (2008) e1797
98. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S.S., Magder L.S., Kreyenbuhl J., Revicki D.A., and Buchanan R.W. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325 (2002) 243
99. Krude H., Biebermann H., and Gruters A. Mutations in the human proopiomelanocortin gene. Ann. NY Acad. Sci. 994 (2003) 233-239
100. Kuriyama S.N., Wanner A., Fidalgo-Neto A.A., Talsness C.E., Koerner W., and Chahoud I. Developmental exposure to low-dose PBDE-99: tissue distribution and thyroid hormone levels. Toxicology 242 (2007) 80-90
101. Lapinskas P.J., Brown S., Leesnitzer L.M., Blanchard S., Swanson C., Cattley R.C., and Corton J.C. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. Toxicology 207 (2005) 149-163
102. Larsen T.M., Toubro S., and Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 147-161
103. Lee H.M., He Q., Englander E.W., and Greeley Jr. G.H. Endocrine disruptive effects of polychlorinated aromatic hydrocarbons on intestinal cholecystokinin in rats. Endocrinology 141 (2000) 2938-2944
104. Lephart E.D., Setchell K.D., Handa R.J., and Lund T.D. Behavioral effects of endocrine-disrupting substances: phytoestrogens. Ilar J. 45 (2004) 443-454
105. Levin B.E. Metabolic imprinting: critical impact of the perinatal environment on the regulation of energy homeostasis. Philos. Trans. R Soc. Lond. B Biol. Sci. 361 (2006) 1107-1121
106. Lillycrop K.A., Phillips E.S., Jackson A.A., Hanson M.A., and Burdge G.C. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J. Nutr. 135 (2005) 1382-1386
107. Lim J.S., Lee D.H., and Jacobs Jr. D.R. Association of brominated flame retardants with diabetes and metabolic syndrome in the United States population: 2003-2004. Diab. Care (2008)
108. Linden J., Korkalainen M., Lensu S., Tuomisto J., and Pohjanvirta R. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and leptin on hypothalamic mRNA expression of factors participating in food intake regulation in a TCDD-sensitive and a TCDD-resistant rat strain. J. Biochem. Mol. Toxicol. 19 (2005) 139-148
109. Lindsay R.S., Lindsay R.M., Waddell B.J., and Seckl J.R. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 39 (1996) 1299-1305
110. Lisboa P.C., Fagundes A.T., Denolato A.T., Oliveira E., Bonomo I.T., Alves S.B., Curty F.H., Passos M.C., and Moura E.G. Neonatal low-protein diet changes deiodinase activities and pituitary TSH response to TRH in adult rats. Exp. Biol. Med. (Maywood) 233 (2008) 57-63
111. Lo S., Allera A., Albers P., Heimbrecht J., Jantzen E., Klingmuller D., and Steckelbroeck S. Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism. J. Steroid Biochem. Mol. Biol. 84 (2003) 569-576
112. Lyssimachou A., Jenssen B.M., and Arukwe A. Brain cytochrome P450 aromatase gene isoforms and activity levels in atlantic salmon after waterborne exposure to nominal environmental concentrations of the pharmaceutical ethynylestradiol and antifoulant tributyltin. Toxicol. Sci. 91 (2006) 82-92
113. Main K.M., Mortensen G.K., Kaleva M.M., Boisen K.A., Damgaard I.N., Chellakooty M., Schmidt I.M., Suomi A.M., Virtanen H.E., Petersen D.V., Andersson A.M., Toppari J., and Skakkebaek N.E. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ. Health Perspect. 114 (2006) 270-276
114. Maloney E.K., and Waxman D.J. trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161 (1999) 209-218
115. Martinez-Hernandez A., Enriquez L., Moreno-Moreno M.J., and Marti A. Genetics of obesity. Public Health Nutr. 10 (2007) 1138-1144
116. Masuno H., Kidani T., Sekiya K., Sakayama K., Shiosaka T., Yamamoto H., and Honda K. Bisphenol A in combination with insulin can accelerate the conversion of 3T3-L1 fibroblasts to adipocytes. J. Lipid Res. 43 (2002) 676-684
117. Masuno H., Iwanami J., Kidani T., Sakayama K., and Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol. Sci. 84 (2005) 319-327
118. Masuo Y., Morita M., Oka S., and Ishido M. Motor hyperactivity caused by a deficit in dopaminergic neurons and the effects of endocrine disruptors: a study inspired by the physiological roles of PACAP in the brain. Regul. Pept. 123 (2004) 225-234
119. Masuo Y., Ishido M., Morita M., and Oka S. Effects of neonatal treatment with 6-hydroxydopamine and endocrine disruptors on motor activity and gene expression in rats. Neural Plast. 11 (2004) 59-76
120. Matsumoto T., Takeyama K., Sato T., and Kato S. Androgen receptor functions from reverse genetic models. J. Steroid Biochem. Mol. Biol. 85 (2003) 95-99
121. McAllister B.G., and Kime D.E. Early life exposure to environmental levels of the aromatase inhibitor tributyltin causes masculinisation and irreversible sperm damage in zebrafish (Danio rerio). Aquat. Toxicol. 65 (2003) 309-316
122. Miltenberger R.J., Mynatt R.L., Wilkinson J.E., and Woychik R.P. The role of the agouti gene in the yellow obese syndrome. J. Nutr. 127 (1997) 1902S-1907S
123. Miyawaki J., Sakayama K., Kato H., Yamamoto H., and Masuno H. Perinatal and postnatal exposure to bisphenol a increases adipose tissue mass and serum cholesterol level in mice. J. Atheroscler. Thromb. 14 (2007) 245-252
124. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., and Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
125. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J., Sewter C.P., Digby J.E., Mohammed S.N., Hurst J.A., Cheetham C.H., Earley A.R., Barnett A.H., Prins J.B., and O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 (1997) 903-908
126. Moura E.G., Santos R.S., Lisboa P.C., Alves S.B., Bonomo I.T., Fagundes A.T., Oliveira E., and Passos M.C. Thyroid function and body weight programming by neonatal hyperthyroidism in rats-the role of leptin and deiodinase activities. Horm. Metab. Res. 40 (2008) 1-7
127. Mu Y.M., Yanase T., Nishi Y., Waseda N., Oda T., Tanaka A., Takayanagi R., and Nawata H. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem. Biophys. Res. Commun. 271 (2000) 710-713
128. Murata Y., Robertson K.M., Jones M.E., and Simpson E.R. Effect of estrogen deficiency in the male: the ArKO mouse model. Mol. Cell Endocrinol. 193 (2002) 7-12
129. Naaz A., Yellayi S., Zakroczymski M.A., Bunick D., Doerge D.R., Lubahn D.B., Helferich W.G., and Cooke P.S. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 144 (2003) 3315-3320
130. Nakano R., Kurosaki E., Yoshida S., Yokono M., Shimaya A., Maruyama T., and Shibasaki M. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem. Pharmacol. 72 (2006) 42-52
131. Nakatsu Y., Kotake Y., Hino A., and Ohta S. Activation of AMP-activated protein kinase by tributyltin induces neuronal cell death. Toxicol. Appl. Pharmacol. (2008)
132. Nath M. Toxicity and the cardiovascular activity of organotin compounds: a review. Appl. Organometall. Chem. 22 (2008) 598-612
133. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry 58 Suppl 10 (1997) 45-49
134. Newbold R.R., Padilla-Banks E., Snyder R.J., and Jefferson W.N. Perinatal exposure to environmental estrogens and the development of obesity. Mol. Nutr. Food Res. 51 (2007) 912-917
135. Newbold R.R., Padilla-Banks E., Snyder R.J., Phillips T.M., and Jefferson W.N. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod. Toxicol. 23 (2007) 290-296
136. Nishiu J., Ito M., Ishida Y., Kakutani M., Shibata T., Matsushita M., and Shindo M. JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo. Diab. Obes. Metab. 8 (2006) 508-516
137. Nonogaki K., Nozue K., and Oka Y. Social isolation affects the development of obesity and type 2 diabetes in mice. Endocrinology 148 (2007) 4658-4666
138. Nyirenda M.J., Lindsay R.S., Kenyon C.J., Burchell A., and Seckl J.R. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J. Clin. Invest. 101 (1998) 2174-2181
139. Oberlander T.F., Weinberg J., Papsdorf M., Grunau R., Misri S., and Devlin A.M. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 3 (2008) 97-106
140. Odermatt A., and Gumy C. Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals?. Biochem. Pharmacol. 76 (2008) 1184-1193
141. Odermatt A., Gumy C., Atanasov A.G., and Dzyakanchuk A.A. Disruption of glucocorticoid action by environmental chemicals: potential mechanisms and relevance. J. Steroid Biochem. Mol. Biol. 102 (2006) 222-231
142. Ohno H., Suzuki M., Nakashima S., Aoyama T., and Mitani K. Determination of organotin compounds in plastic products by GC/MS after ethyl derivatization with sodium tetraethylborate. Shokuhin Eiseigaku Zasshi 43 (2002) 208-214
143. Oken E., Huh S.Y., Taveras E.M., Rich-Edwards J.W., and Gillman M.W. Associations of maternal prenatal smoking with child adiposity and blood pressure. Obes. Res. 13 (2005) 2021-2028
144. Parks L.G., Ostby J.S., Lambright C.R., Abbott B.D., Klinefelter G.R., Barlow N.J., and Gray Jr. L.E. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol. Sci. 58 (2000) 339-349
145. Pasquali R., Vicennati V., Cacciari M., and Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann. NY Acad. Sci. 1083 (2006) 111-128
146. Penza M., Montani C., Romani A., Vignolini P., Pampaloni B., Tanini A., Brandi M.L., Alonso-Magdalena P., Nadal A., Ottobrini L., Parolini O., Bignotti E., Calza S., Maggi A., Grigolato P.G., and Di Lorenzo D. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 147 (2006) 5740-5751
147. Phrakonkham P., Viengchareun S., Belloir C., Lombes M., Artur Y., and Canivenc-Lavier M.C. Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. J. Steroid Biochem. Mol. Biol. (2008)
148. Power C., and Jefferis B.J. Fetal environment and subsequent obesity: a study of maternal smoking. Int. J. Epidemiol. 31 (2002) 413-419
149. Rantakokko P., Turunen A., Verkasalo P.K., Kiviranta H., Mannisto S., and Vartiainen T. Blood levels of organotin compounds and their relation to fish consumption in Finland. Sci. Total Environ. (2008)
150. Raposinho P.D., Pierroz D.D., Broqua P., White R.B., Pedrazzini T., and Aubert M.L. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol. Cell Endocrinol. 185 (2001) 195-204
151. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 640-648
152. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., and Wahli W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. 16 (2002) 2628-2644
153. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., and Kahn C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339 (1998) 953-959
154. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., and Mortensen R.M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 (1999) 611-617
155. Rosen M.B., Lee J.S., Ren H., Vallanat B., Liu J., Waalkes M.P., Abbott B.D., Lau C., and Corton J.C. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. Toxicol. Sci. 103 (2008) 46-56
156. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., and Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta (2007)
157. Rubin M.M. Antenatal exposure to DES: lessons learned. future concerns. Obstet. Gynecol. Surv. 62 (2007) 548-555
158. Rubin B.S., Murray M.K., Damassa D.A., King J.C., and Soto A.M. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ. Health Perspect. 109 (2001) 675-680
159. Ruetsch O., Viala A., Bardou H., Martin P., and Vacheron M.N. Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encephale 31 (2005) 507-516
160. Ruhlen R.L., Howdeshell K.L., Mao J., Taylor J.A., Bronson F.H., Newbold R.R., Welshons W.V., and vom Saal F.S. Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice. Environ. Health Perspect. 116 (2008) 322-328
161. Rusyn I., Peters J.M., and Cunningham M.L. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit. Rev. Toxicol. 36 (2006) 459-479
162. Sadamatsu M., Tsunashima K., Schwarzer C., Takahashi Y., Kato N., and Sperk G. Trimethyltin-induced expression of neuropeptide Y Y2 receptors in rat dentate gyrus. Neurotoxicol. Teratol. 20 (1998) 607-610
163. Sadiki A.I., and Williams D.T. A study on organotin levels in Canadian drinking water distributed through PVC pipes. Chemosphere 38 (1999) 1541-1548
164. Saitoh M., Yanase T., Morinaga H., Tanabe M., Mu Y.M., Nishi Y., Nomura M., Okabe T., Goto K., Takayanagi R., and Nawata H. Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell line KGN. Biochem. Biophys. Res. Commun. 289 (2001) 198-204
165. Sakata I., Tanaka T., Yamazaki M., Tanizaki T., Zheng Z., and Sakai T. Gastric estrogen directly induces ghrelin expression and production in the rat stomach. J. Endocrinol. 190 (2006) 749-757
166. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., and Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
167. Sakurai K., Kawazuma M., Adachi T., Harigaya T., Saito Y., Hashimoto N., and Mori C. Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. Br. J. Pharmacol. 141 (2004) 209-214
168. Shimasaki Y., Kitano T., Oshima Y., Inoue S., Imada N., and Honjo T. Tributyltin causes masculinization in fish. Environ. Toxicol. Chem. 22 (2003) 141-144
169. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. (Lond.) 29 (2005) 755-759
170. Sipols A.J., Bayer J., Bennett R., and Figlewicz D.P. Intraventricular insulin decreases kappa opioid-mediated sucrose intake in rats. Peptides 23 (2002) 2181-2187
171. Stahlhut R.W., van Wijgaarden E., Dye T.D., Cook S., and Swan S.H. Concentrations of urinary phthalate metabolites are associated with increased waist circumferece and insulin resistance in adult U.S. males. Environ. Health Perspect. 115 (2007) 876-882
172. Stocker C.J., Arch J.R., and Cawthorne M.A. Fetal origins of insulin resistance and obesity. Proc. Nutr. Soc. 64 (2005) 143-151
173. Strand J., and Jacobsen J.A. Accumulation and trophic transfer of organotins in a marine food web from the Danish coastal waters. Sci. Total Environ. 350 (2005) 72-85
174. State-specific prevalence of obesity among adults--United States, 2005. MMWR Morb. Mortal Wkly. Rep. 55 (2006) 985-988
175. Swan S.H., Main K.M., Liu F., Stewart S.L., Kruse R.L., Calafat A.M., Mao C.S., Redmon J.B., Ternand C.L., Sullivan S., and Teague J.L. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ. Health Perspect. 113 (2005) 1056-1061
176. Takahashi S., Mukai H., Tanabe S., Sakayama K., Miyazaki T., and Masuno H. Butyltin residues in livers of humans and wild terrestrial mammals and in plastic products. Environ. Pollut. 106 (1999) 213-218
177. Takeuchi T., Tsutsumi O., Ikezuki Y., Takai Y., and Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr. J. 51 (2004) 165-169
178. Talsness C.E., Kuriyama S.N., Sterner-Kock A., Schnitker P., Grande S.W., Shakibaei M., Andrade A., Grote K., and Chahoud I. In utero and lactational exposures to low doses of polybrominated diphenyl ether-47 alter the reproductive system and thyroid gland of female rat offspring. Environ. Health Perspect. 116 (2008) 308-314
179. Theander-Carrillo C., Wiedmer P., Cettour-Rose P., Nogueiras R., Perez-Tilve D., Pfluger P., Castaneda T.R., Muzzin P., Schurmann A., Szanto I., Tschop M.H., and Rohner-Jeanrenaud F. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 116 (2006) 1983-1993
180. Thomas P., and Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol. 102 (2006) 175-179
181. Titolo D., Cai F., and Belsham D.D. Coordinate regulation of neuropeptide Y and agouti-related peptide gene expression by estrogen depends on the ratio of estrogen receptor (ER) alpha to ERbeta in clonal hypothalamic neurons. Mol. Endocrinol. 20 (2006) 2080-2092
182. Tschop M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
183. Tsuda T., Inoue T., Kojima M., and Aoki S. Daily intakes of tributyltin and triphenyltin compounds from meals. J. AOAC Int. 78 (1995) 941-943
184. Tsumura Y., Ishimitsu S., Saito I., Sakai H., Kobayashi Y., and Tonogai Y. Eleven phthalate esters and di(2-ethylhexyl) adipate in one-week duplicate diet samples obtained from hospitals and their estimated daily intake. Food Addit. Contam. 18 (2001) 449-460
185. Tsumura Y., Ishimitsu S., Saito I., Sakai H., Tsuchida Y., and Tonogai Y. Estimated daily intake of plasticizers in 1-week duplicate diet samples following regulation of DEHP-containing PVC gloves in Japan. Food Addit. Contam. 20 (2003) 317-324
186. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
187. van Abeelen A.F., de Krom M., Hendriks J., Grobbee D.E., Adan R.A., and van der Schouw Y.T. Variations in the uncoupling protein-3 gene are associated with specific obesity phenotypes. Eur. J. Endocrinol. 158 (2008) 669-676
188. van Gelderen C.E., Bijlsma J.A., van Dokkum W., and Savelkoul T.J. Glycyrrhizic acid: the assessment of a no effect level. Hum. Exp. Toxicol. 19 (2000) 434-439
189. Vanden Heuvel J.P., Thompson J.T., Frame S.R., and Gillies P.J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci. 92 (2006) 476-489
190. Vermorel M., Lazzer S., Bitar A., Ribeyre J., Montaurier C., Fellmann N., Coudert J., Meyer M., and Boirie Y. Contributing factors and variability of energy expenditure in non-obese, obese, and post-obese adolescents. Reprod. Nutr. Dev. 45 (2005) 129-142
191. Vestri H.S., Maianu L., Moellering D.R., and Garvey W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32 (2007) 765-772
192. vom Saal F.S., Akingbemi B.T., Belcher S.M., Birnbaum L.S., Crain D.A., Eriksen M., Farabollini F., Guillette Jr. L.J., Hauser R., Heindel J.J., Ho S.M., Hunt P.A., Iguchi T., Jobling S., Kanno J., Keri R.A., Knudsen K.E., Laufer H., LeBlanc G.A., Marcus M., McLachlan J.A., Myers J.P., Nadal A., Newbold R.R., Olea N., Prins G.S., Richter C.A., Rubin B.S., Sonnenschein C., Soto A.M., Talsness C.E., Vandenbergh J.G., Vandenberg L.N., Walser-Kuntz D.R., Watson C.S., Welshons W.V., Wetherill Y., and Zoeller R.T. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod. Toxicol. 24 (2007) 131-138
193. Warren J.R., Lalwani N.D., and Reddy J.K. Phthalate esters as peroxisome proliferator carcinogens. Environ. Health Perspect. 45 (1982) 35-40
194. Watson C.S., Bulayeva N.N., Wozniak A.L., and Alyea R.A. Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids 72 (2007) 124-134
195. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., and Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 7 (2004) 847-854
196. Welberg L.A., Seckl J.R., and Holmes M.C. Inhibition of 11beta-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. Eur. J. Neurosci. 12 (2000) 1047-1054
197. Williams C.M., and Kirkham T.C. Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol. Behav. 76 (2002) 241-250
198. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., and Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry 63 (2002) 856-865
199. Wolf C.J., Fenton S.E., Schmid J.E., Calafat A.M., Kuklenyik Z., Bryant X.A., Thibodeaux J., Das K.P., White S.S., Lau C.S., and Abbott B.D. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol. Sci. 95 (2007) 462-473
200. Wu J., Oka J., Tabata I., Higuchi M., Toda T., Fuku N., Ezaki J., Sugiyama F., Uchiyama S., Yamada K., and Ishimi Y. Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. J. Bone Miner. Res. 21 (2006) 780-789
201. Xie Y., Yang Q., Nelson B.D., and DePierre J.W. Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice. Lipids 37 (2002) 139-146
202. Xie Y., Yang Q., Nelson B.D., and DePierre J.W. The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome proliferator exposure and withdrawal in mice. Biochem. Pharmacol. 66 (2003) 749-756
203. Yajnik C. Interactions of perturbations in intrauterine growth and growth during childhood on the risk of adult-onset disease. Proc. Nutr. Soc. 59 (2000) 257-265
204. Yang L.H., Chen T.M., Yu S.T., and Chen Y.H. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol. Res. 56 (2007) 202-208
205. Yun A.J., Bazar K.A., Lee P.Y., Gerber A., and Daniel S.M. The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. Med. Hypotheses 64 (2005) 1073-1079
206. Zhao Z., Sakata I., Okubo Y., Koike K., Kangawa K., and Sakai T. Gastric leptin, but not estrogen and somatostatin, contributes to the elevation of ghrelin mRNA expression level in fasted rats. J. Endocrinol. 196 (2008) 529-538